332 related articles for article (PubMed ID: 19843843)
21. Using microRNA profiling in urine samples to develop a non-invasive test for bladder cancer.
Mengual L; Lozano JJ; Ingelmo-Torres M; Gazquez C; Ribal MJ; Alcaraz A
Int J Cancer; 2013 Dec; 133(11):2631-41. PubMed ID: 23686449
[TBL] [Abstract][Full Text] [Related]
22. Dicer ablation promotes a mesenchymal and invasive phenotype in bladder cancer cells.
Lombard AP; Lim RM; Nakagawa RM; Vidallo KD; Libertini SJ; Platero AJ; Mudryj M
Oncol Rep; 2015 Sep; 34(3):1526-32. PubMed ID: 26166215
[TBL] [Abstract][Full Text] [Related]
23. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma.
Jebar AH; Hurst CD; Tomlinson DC; Johnston C; Taylor CF; Knowles MA
Oncogene; 2005 Aug; 24(33):5218-25. PubMed ID: 15897885
[TBL] [Abstract][Full Text] [Related]
24. Expression of miR-100 and miR-138 as prognostic biomarkers in non-muscle-invasive bladder cancer.
Blanca A; Sanchez-Gonzalez A; Requena MJ; Carrasco-Valiente J; Gomez-Gomez E; Cheng L; Cimadamore A; Montironi R; Lopez-Beltran A
APMIS; 2019 Aug; 127(8):545-553. PubMed ID: 31231851
[TBL] [Abstract][Full Text] [Related]
25. Stage, grade and behavior of bladder urothelial carcinoma defined by the microRNA expression profile.
Dip N; Reis ST; Timoszczuk LS; Viana NI; Piantino CB; Morais DR; Moura CM; Abe DK; Silva IA; Srougi M; Dall'Oglio MF; Leite KR
J Urol; 2012 Nov; 188(5):1951-6. PubMed ID: 22999546
[TBL] [Abstract][Full Text] [Related]
26. [Current knowledge in molecular pathology of urothelial cancer].
Knüchel-Clarke R; Dahl E; Gaisa NT; Schwamborn K; Lindemann-Docter K; Henkel C
Pathologe; 2010 Oct; 31 Suppl 2():234-8. PubMed ID: 20665023
[TBL] [Abstract][Full Text] [Related]
27. Impact of EZH2 polymorphisms on urothelial cell carcinoma susceptibility and clinicopathologic features.
Yu YL; Su KJ; Hsieh MJ; Wang SS; Wang PH; Weng WC; Yang SF
PLoS One; 2014; 9(4):e93635. PubMed ID: 24691023
[TBL] [Abstract][Full Text] [Related]
28. No mutations of FGFR3 in normal urothelium in the vicinity of urothelial carcinoma of the bladder harbouring activating FGFR3 mutations in patients with bladder cancer.
Otto W; Denzinger S; Bertz S; Gaumann A; Wild PJ; Hartmann A; Stoehr R
Int J Cancer; 2009 Nov; 125(9):2205-8. PubMed ID: 19621447
[TBL] [Abstract][Full Text] [Related]
29. Downregulation of miR-133b predict progression and poor prognosis in patients with urothelial carcinoma of bladder.
Chen X; Wu B; Xu Z; Li S; Tan S; Liu X; Wang K
Cancer Med; 2016 Aug; 5(8):1856-62. PubMed ID: 27292588
[TBL] [Abstract][Full Text] [Related]
30. Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking: contribution of exogenous versus endogenous carcinogens.
Wallerand H; Bakkar AA; de Medina SG; Pairon JC; Yang YC; Vordos D; Bittard H; Fauconnet S; Kouyoumdjian JC; Jaurand MC; Zhang ZF; Radvanyi F; Thiery JP; Chopin DK
Carcinogenesis; 2005 Jan; 26(1):177-84. PubMed ID: 15347601
[TBL] [Abstract][Full Text] [Related]
31. Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer.
Genitsch V; Kollár A; Vandekerkhove G; Blarer J; Furrer M; Annala M; Herberts C; Pycha A; de Jong JJ; Liu Y; Krentel F; Davicioni E; Gibb EA; Kruithof-de Julio M; Wyatt AW; Seiler R
Urol Oncol; 2019 Nov; 37(11):826-836. PubMed ID: 31585777
[TBL] [Abstract][Full Text] [Related]
32. [Histopathology of urothelial carcinomas: crucial for patient management].
Lindemann-Docter K; Knüchel-Clarke R
Urologe A; 2008 May; 47(5):627-36; quiz 637. PubMed ID: 18427766
[TBL] [Abstract][Full Text] [Related]
33. Hypermethylation of CpG islands and shores around specific microRNAs and mirtrons is associated with the phenotype and presence of bladder cancer.
Dudziec E; Miah S; Choudhry HM; Owen HC; Blizard S; Glover M; Hamdy FC; Catto JW
Clin Cancer Res; 2011 Mar; 17(6):1287-96. PubMed ID: 21138856
[TBL] [Abstract][Full Text] [Related]
34. microRNA expression profile in a large series of bladder tumors: identification of a 3-miRNA signature associated with aggressiveness of muscle-invasive bladder cancer.
Pignot G; Cizeron-Clairac G; Vacher S; Susini A; Tozlu S; Vieillefond A; Zerbib M; Lidereau R; Debre B; Amsellem-Ouazana D; Bieche I
Int J Cancer; 2013 Jun; 132(11):2479-91. PubMed ID: 23169479
[TBL] [Abstract][Full Text] [Related]
35. [Recent advances in molecular pathology of bladder cancer].
Cheng L; Xu JW; Teng XD; Zhao J
Zhonghua Bing Li Xue Za Zhi; 2011 Nov; 40(11):779-82. PubMed ID: 22336167
[No Abstract] [Full Text] [Related]
36. DNA damage in cytologically normal urothelial cells of patients with a history of urothelial cell carcinoma.
Gontijo AM; Marcondes JP; Elias FN; de Oliveira ML; de Lima RO; Salvadori DM; de Camargo JL
Environ Mol Mutagen; 2002; 40(3):190-9. PubMed ID: 12355553
[TBL] [Abstract][Full Text] [Related]
37. TERT promoter mutations and TERT mRNA but not FGFR3 mutations are urinary biomarkers in Han Chinese patients with urothelial bladder cancer.
Wang K; Liu T; Liu C; Meng Y; Yuan X; Liu L; Ge N; Liu J; Wang C; Ren H; Yan K; Hu S; Xu Z; Fan Y; Xu D
Oncologist; 2015 Mar; 20(3):263-9. PubMed ID: 25657201
[TBL] [Abstract][Full Text] [Related]
38. The Emerging Molecular Landscape of Urothelial Carcinoma.
Solomon JP; Hansel DE
Surg Pathol Clin; 2016 Sep; 9(3):391-404. PubMed ID: 27523968
[TBL] [Abstract][Full Text] [Related]
39. Role of the angiogenic components, VEGFA, FGF2, OPN and RHOC, in urothelial cell carcinoma of the urinary bladder.
Zaravinos A; Volanis D; Lambrou GI; Delakas D; Spandidos DA
Oncol Rep; 2012 Oct; 28(4):1159-66. PubMed ID: 22895562
[TBL] [Abstract][Full Text] [Related]
40. Effect of
Hung SC; Wang SS; Li JR; Chen CS; Yang CK; Chiu KY; Cheng CL; Ou YC; Ho HC; Yang SF
Int J Med Sci; 2018; 15(14):1731-1736. PubMed ID: 30588197
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
